The Future of Single Cell Analysis….. COVID-19 & Its Impact….
The global single cell
analysis market size is expected
to reach USD 8.02 billion by 2027,
registering a CAGR of 16.9% during the forecast period, according to a new
report by Grand View Research, Inc. Advancements in molecular techniques which
resulted in higher accuracy, ability to perform multiple omics analyses in one
cell, and automation, has lowered the barriers for implementation of
single-cell analysis techniques across various end-use settings. As a result,
companies are investing in introducing novel solutions to accelerate the
identification and quantification of genetic information in individual cells
for research programs, thereby contributing to revenue growth in this market.
Biopharmaceutical innovators are at the
forefront of the human response to the coronavirus pandemic. A significant
number of major biotech firms are in the midst of a race to investigate the
Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the
speed of response to SARS/MERs etc, the biotech entities are investigating
SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are
being put into the R&D. With multiple candidates in trial, the public and
private sectors are anticipated to work in unison for the foreseeable period,
until a vaccine is developed for Covid-19. The report will account for Covid19
as a key market contributor.
This technology has addressed several
research challenges with respect to biological intricacies in stem cell
biology, tumor biology, immunology, and other therapeutic areas. This leads to
improved therapeutic decision-making with regards to precision medicine,
thereby driving the adoption of these assays in personalized therapeutic
development.
The growth in research publications
depicts the increasing R&D investments. Since R&D activities are
considered as the foundation of innovation, investments in R&D activities
signify a healthy growth prospect for the single cell analysis market.
Moreover, the establishment of new single cell genomics centers in the past
years is anticipated to boost the uptake of instruments and consumables for
single cell analysis, thus driving the growth.
To Request Sample Copy of this report, click the link:
Further key findings from the report suggest:
·
Consumables accounted for the
major revenue share in 2020 owing to the continuous demand and repeated
purchase of products offered under this segment
·
Introduction of automated
instruments is anticipated to boost the revenue growth for instrument segment
·
Cancer biology is one of the
majorly benefitted applications of single-cell analysis
·
Investigation at the individual
cellular level has resolved several concerns associated with tumor mechanism
and drug response, which has fomented the uptake of this technology analysis in
cancer biology
·
Single cell analysis is being
researched and employed across various end-use settings ranging from academic
research institutes to biopharmaceutical companies
·
However, since it is in infant
stage in the current mark, majorly it is employed with research end-user
settings
·
Hospitals and diagnostic
laboratories segment is expected to emerge as the lucrative source of revenue
in the forthcoming years, due to the ongoing efforts to bridge the gap for
implementation of OMICs technology from research laboratories to clinical
settings
·
North America dominated the
global revenue share in 2020, owing to the continuous strategies undertaken in
U.S. for development of robust therapies and advance the disease diagnosis
·
Asia Pacific is estimated to
expand at the fastest CAGR over the forecast period with China & India at
the forefront. A high number of CAR T clinical trials in China and low
operating cost for clinical trials in India would contribute to the anticipated
growth
·
Some key players operating in
the Single cell analysis market are Illumina, Inc.; Qiagen N.V.; Thermo Fisher
Scientific, Inc.; Merck Millipore GmbH; Bio-Rad Laboratories, Inc.; Fluidigm,
BGI; 10x Genomics, Inc.; and Novogene Corporation
·
Companies like Illumina and
Qiagen are expected to gain competitive advantage on account of their wide
sequencing portfolio. On the other hand, companies like 10x Genomics, Inc. are
anticipated to witness significant organic revenue growth owing to wide product
portfolio
The global single cell analysis market
size was estimated at 2.29 billion in 2020 and is projected to expand at a CAGR
of 16.9% during the forecast period. Recent developments in the OMICs method
with respect to technology, specificity, scale, and timelines, have enabled a
comprehensive analysis of transcriptome and genome at an individual cellular
level. Moreover, technological advancements in Single cell manipulation and
amplification techniques have led to the implementation of high throughput
technologies in assays, in turn driving the revenue growth.
Ongoing technological advancements,
such as the advent of Single cell RNA sequencing, have opened new research
avenues for the detection of molecular changes which aids in disease etiology
for specific cell types. This application enhances the identification of highly
specific and diagnostic biomarkers, as well as therapeutic targets, consequently
increasing adoption within both the diagnostic and pharmaceutical industries.
Browse Press
Release of this report:
Grand View Research has segmented the
global single cell analysis market on the basis of product, application, end
use:
Single-cell Analysis Product Outlook (Revenue, USD
Million, 2016 - 2027)
·
Consumables
o Reagents
o Assay Kits
o Other Consumables
·
Instruments
o Manual Instruments
o Microscopes
o Hemocytometers
o Automated Instruments
o Flow cytometers
o Next Generation Sequencing
o PCR Systems
o High-content Screening System
o Cell Microarrays
o Automated Cell Counters
Single-cell Analysis Application Outlook (Revenue, USD
Million, 2016 - 2027)
·
Cancer
·
Immunology
·
Neurology
·
Stem Cell
·
Non-invasive Prenatal Diagnosis
·
In-vitro Fertilization
Single-cell Analysis End-use Outlook (Revenue, USD
Million, 2016 - 2027)
·
Academic & Research
Laboratories
·
Biotechnology and
Pharmaceutical Companies
·
Hospitals and Diagnostic
Laboratories
·
Others
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Comments
Post a Comment